Table 2.

Examples of non-inferiority trials of reduced intensity therapies included in the analysis. See online appendix 1 for a full bibliography of all 31 trials

First author	Disease	Experimental therapy	Active control	Outcome
Anderson29	Ischaemic stroke	Low-dose alteplase	Standard dose alteplase	Death or disability at 90 days
Johnson11	Hodgkin’s lymphoma	ABV	ABVD	3-year progression free survival
Sherman30	Hepatitis C virus infection	24 weeks telaprevir	48 weeks telaprevir	Sustained virological response
Pritchard-Jones31	Wilms' tumour	Omission of doxorubicin	Inclusion of doxorubicin	Event-free survival 2 years after diagnosis
Bernard32	Pyogenic vertebral osteomyelitis	6 weeks of antibiotics	12 weeks of antibiotics	Clinical cure rate
Vaidya33	Breast cancer	Targeted radiotherapy	Whole breast radiotherapy	Local recurrence rate
van Herwaarden34	Rheumatoid arthritis	Withdrawal of adalimumab or etanercept	Continuation of adalimumab or etanercept	Rate of major flare at 18 months
Feres35	Coronary stenting	3 months antiplatelet therapy	12 months antiplatelet therapy	Net adverse clinical and cerebral events
Rahman36	Malignant pleural effusions	12 French tube	24 French tube	Pleurodesis efficacy
Barone37	Genital fistula	7 days postoperative bladder catheterisation	14 days postoperative bladder catheterisation	Repair breakdown rate

ABV, Adriamycin, bleomycin, vinblastine; ABVD, Adriamycin, bleomycin, vinblastine, dacarbazine.